All In Biotech

Drug Trial Radar · NCT06964009

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

A Phase 1b Study of BCL-XL Degrader DT2216 in Combination With Weekly Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 22, 2025

Primary completion

Jun 30, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Elizabeth Stover, MD, PhDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
United States Department of Defense; Dialectic Therapeutics, Inc; American Society of Clinical Oncology
First posted
May 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian and endometrial cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)

Conditions

  • Ovarian Cancer
  • Ovarian Carcinoma
  • Recurrent Ovary Cancer
  • Recurrent Platinum-Resistant Ovarian Carcinoma
  • Endometrial Cancer
  • Endometrial Adenocarcinoma
  • Recurrent Endometrial Carcinoma

Interventions

  • DT2216Drug

    A proteolysis-targeting chimera (PROTAC) degrader, single-use vial, via intravenous (into the vein) infusion.

  • PaclitaxelDrug

    An antimicrotubule agent, multi-dose vial, via intravenous (into the vein) infusion per institutional standard.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DT2216 Maximum Tolerated Dose (MTD)Time frame: Assessed on Day 1, 4, 8, 11, 15, 18, 22 and 25 on cycle 1 and up to start of cycle 2; cycle 1 duration=28 days plus 14 days maximum until start of cycle 2, for a maximum time frame of 42 days.
  2. Number of Participants Experiencing a Dose-Limiting Toxicity (DLT)Time frame: Assessed on Day 1, 4, 8, 11, 15, 18, 22 and 25 on cycle 1 and up to start of cycle 2; cycle 1 duration=28 days plus 14 days maximum until start of cycle 2, for a maximum time frame of 42 days.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Beth Israel Deaconess Medical Center (BIDMC)

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.